CN1582333B - 活疫苗及生产方法 - Google Patents

活疫苗及生产方法 Download PDF

Info

Publication number
CN1582333B
CN1582333B CN018192068A CN01819206A CN1582333B CN 1582333 B CN1582333 B CN 1582333B CN 018192068 A CN018192068 A CN 018192068A CN 01819206 A CN01819206 A CN 01819206A CN 1582333 B CN1582333 B CN 1582333B
Authority
CN
China
Prior art keywords
leu
glu
ser
gly
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN018192068A
Other languages
English (en)
Chinese (zh)
Other versions
CN1582333A (zh
Inventor
H·卡廷格尔
A·埃戈洛夫
B·费尔科
J·罗马诺瓦
D·卡廷格尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Polymun Scientific Immunbiologische Forschung GmbH
Original Assignee
Polymun Scientific Immunbiologische Forschung GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polymun Scientific Immunbiologische Forschung GmbH filed Critical Polymun Scientific Immunbiologische Forschung GmbH
Publication of CN1582333A publication Critical patent/CN1582333A/zh
Application granted granted Critical
Publication of CN1582333B publication Critical patent/CN1582333B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN018192068A 2000-09-25 2001-09-25 活疫苗及生产方法 Expired - Fee Related CN1582333B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00120896 2000-09-25
EP00120896.6 2000-09-25
PCT/EP2001/011087 WO2002024876A2 (en) 2000-09-25 2001-09-25 Live influenza vaccine and method of manufacture

Publications (2)

Publication Number Publication Date
CN1582333A CN1582333A (zh) 2005-02-16
CN1582333B true CN1582333B (zh) 2010-06-16

Family

ID=8169944

Family Applications (1)

Application Number Title Priority Date Filing Date
CN018192068A Expired - Fee Related CN1582333B (zh) 2000-09-25 2001-09-25 活疫苗及生产方法

Country Status (12)

Country Link
US (1) US7494659B2 (https=)
EP (1) EP1358319B1 (https=)
JP (1) JP5063852B2 (https=)
KR (2) KR20030061810A (https=)
CN (1) CN1582333B (https=)
AT (1) ATE434035T1 (https=)
AU (2) AU2002223560B2 (https=)
CA (1) CA2423038C (https=)
DE (1) DE60139026D1 (https=)
DK (1) DK1358319T3 (https=)
ES (1) ES2327103T3 (https=)
WO (1) WO2002024876A2 (https=)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
KR100637937B1 (ko) 1998-06-12 2006-10-23 마운트 시나이 스쿨 오브 메디신 오브 뉴욕 유니버시티 변형된 인터페론 길항물질을 보유하고, 백신 및 약제로사용되는 약독화된 네거티브 가닥 바이러스
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
WO2001077394A1 (en) 2000-04-10 2001-10-18 Mount Sinai School Of Medicine Of New York University Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
US7718354B2 (en) 2001-03-02 2010-05-18 Ibis Biosciences, Inc. Methods for rapid identification of pathogens in humans and animals
US7226739B2 (en) 2001-03-02 2007-06-05 Isis Pharmaceuticals, Inc Methods for rapid detection and identification of bioagents in epidemiological and forensic investigations
US7666588B2 (en) 2001-03-02 2010-02-23 Ibis Biosciences, Inc. Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy
US20030027135A1 (en) 2001-03-02 2003-02-06 Ecker David J. Method for rapid detection and identification of bioagents
US20040121309A1 (en) 2002-12-06 2004-06-24 Ecker David J. Methods for rapid detection and identification of bioagents in blood, bodily fluids, and bodily tissues
US7217510B2 (en) 2001-06-26 2007-05-15 Isis Pharmaceuticals, Inc. Methods for providing bacterial bioagent characterizing information
US8073627B2 (en) 2001-06-26 2011-12-06 Ibis Biosciences, Inc. System for indentification of pathogens
WO2003060088A2 (en) * 2002-01-15 2003-07-24 Acambis, Inc. Viral vaccine production method
ES2526191T3 (es) * 2002-04-26 2015-01-08 Medimmune, Llc Método para producir virus influenza B infeccioso en cultivo celular
US7465456B2 (en) * 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
PT2287288E (pt) 2002-07-09 2012-12-10 Baxter Int Meio isento de proteína animal para cultura de células
JP2005537793A (ja) 2002-09-05 2005-12-15 バヴァリアン・ノルディック・アクティーゼルスカブ 無血清条件下で初代細胞を培養する方法及びウイルスを増幅させる方法
JP2006516193A (ja) 2002-12-06 2006-06-29 アイシス・ファーマシューティカルス・インコーポレーテッド ヒトおよび動物における病原体の迅速な同定方法
US20060110406A1 (en) 2003-02-25 2006-05-25 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions
US7262045B2 (en) 2003-02-25 2007-08-28 Medimmune Vaccines, Inc. Methods of producing influenza vaccine compositions
US8046171B2 (en) 2003-04-18 2011-10-25 Ibis Biosciences, Inc. Methods and apparatus for genetic evaluation
US8057993B2 (en) 2003-04-26 2011-11-15 Ibis Biosciences, Inc. Methods for identification of coronaviruses
US8158354B2 (en) 2003-05-13 2012-04-17 Ibis Biosciences, Inc. Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US7964343B2 (en) 2003-05-13 2011-06-21 Ibis Biosciences, Inc. Method for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US7566458B2 (en) 2003-06-16 2009-07-28 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
AU2004249802B2 (en) 2003-06-20 2007-06-28 Microbix Biosystems Inc. Improvements in virus production
US7956175B2 (en) 2003-09-11 2011-06-07 Ibis Biosciences, Inc. Compositions for use in identification of bacteria
US8546082B2 (en) 2003-09-11 2013-10-01 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US8097416B2 (en) 2003-09-11 2012-01-17 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
ATE469972T1 (de) * 2003-12-23 2010-06-15 Medimmune Llc Multiplasmid-system zur erzeugung des grippevirus
US7666592B2 (en) 2004-02-18 2010-02-23 Ibis Biosciences, Inc. Methods for concurrent identification and quantification of an unknown bioagent
US8119336B2 (en) 2004-03-03 2012-02-21 Ibis Biosciences, Inc. Compositions for use in identification of alphaviruses
US20060024670A1 (en) 2004-05-18 2006-02-02 Luke Catherine J Influenza virus vaccine composition and methods of use
EP2458619B1 (en) 2004-05-24 2017-08-02 Ibis Biosciences, Inc. Mass spectrometry with selective ion filtration by digital thresholding
US20050266411A1 (en) 2004-05-25 2005-12-01 Hofstadler Steven A Methods for rapid forensic analysis of mitochondrial DNA
CA2879182C (en) 2004-05-25 2017-02-14 Medimmune, Inc. Influenza hemagglutinin and neuraminidase variants
EP3332803B1 (en) 2004-06-01 2021-09-08 Icahn School of Medicine at Mount Sinai Genetically engineered swine influenza virus and uses thereof
WO2006033691A2 (en) * 2004-07-02 2006-03-30 Niman Henry L Copy choice recombination and uses thereof
US7811753B2 (en) 2004-07-14 2010-10-12 Ibis Biosciences, Inc. Methods for repairing degraded DNA
WO2006135400A2 (en) 2004-08-24 2006-12-21 Isis Pharmaceuticals, Inc. Methods for rapid identification of recombinant organisms
US20060094104A1 (en) * 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
AU2011221414B2 (en) * 2004-10-29 2012-09-20 Takeda Pharmaceutical Company Limited Animal Protein-Free Media for Cultivation of Cells
WO2006088481A2 (en) 2005-02-15 2006-08-24 Mount Sinai School Of Medicine Of New York University Genetically engineered equine influenza virus and uses thereof
WO2006094238A2 (en) 2005-03-03 2006-09-08 Isis Pharmaceuticals, Inc. Compositions for use in identification of adventitious viruses
US8084207B2 (en) 2005-03-03 2011-12-27 Ibis Bioscience, Inc. Compositions for use in identification of papillomavirus
EP2441471B1 (en) 2005-03-08 2014-10-08 MedImmune, LLC Reassortant influenza viruses
BRPI0613287A2 (pt) 2005-06-17 2010-12-28 Sanofi Pasteur cepa do vìrus da dengue-2 vivo atenuada, composição imunogênica, composição de vacina, ácido nucléico isolado, poliproteìna isolada codificadas pela seq id n .1 ou fragmentos desta e fragmento da poliproteìna
CN101238144B (zh) 2005-06-17 2012-09-05 赛诺菲巴斯德有限公司 登革血清型1减毒株
CA2616281C (en) 2005-07-21 2014-04-22 Isis Pharmaceuticals, Inc. Methods for rapid identification and quantitation of mitochondrial dna variants
US20070111309A1 (en) * 2005-10-04 2007-05-17 Daelli Marcelo G Vero cell line adapted to grow in suspension
US20070087336A1 (en) * 2005-10-17 2007-04-19 Rangarajan Sampath Compositions for use in identification of influenza viruses
EP3653699A1 (en) 2006-01-04 2020-05-20 Baxalta Incorporated Oligopeptide-free cell culture media
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
GB0605247D0 (en) * 2006-03-15 2006-04-26 Chiron Srl Compositions and methods for immunisation
US9642907B2 (en) * 2006-05-12 2017-05-09 Bharat Biotech International Limited Stabilized liquid rotavirus vaccine composition
WO2008133701A1 (en) * 2006-07-21 2008-11-06 Medimmune, Llc. Methods and compositions for increasing replication capacity of an influenza virus
EP2056872A4 (en) * 2006-08-09 2016-12-21 Medimmune Llc INFLUENZA HEMAGGLUTININE AND NEURAMINIDASE VARIANTS
JP5420412B2 (ja) 2006-09-14 2014-02-19 アイビス バイオサイエンシズ インコーポレイティッド 病原体の同定のための標的全ゲノム増幅方法
EP1911836A1 (en) * 2006-10-12 2008-04-16 AVIR Green Hills Biotechnology Trading GmbH Medium supplement for virus production
JP5680304B2 (ja) 2007-02-23 2015-03-04 アイビス バイオサイエンシズ インコーポレイティッド 迅速な法医学的ｄｎａ分析法
US9598724B2 (en) 2007-06-01 2017-03-21 Ibis Biosciences, Inc. Methods and compositions for multiple displacement amplification of nucleic acids
CA2690196A1 (en) 2007-06-18 2008-12-24 Medimmune, Llc Influenza b viruses having alterations in the hemaglutinin polypeptide
US8198256B2 (en) * 2007-07-03 2012-06-12 Kyorin Pharmaceutical Co., Ltd. Treatment of influenza
US8084594B2 (en) * 2007-07-13 2011-12-27 The United States Of America As Represented By The Secretary Of Agriculture H2N3 influenza A viruses and methods of use
WO2010006144A2 (en) * 2008-07-11 2010-01-14 Medlmmune, Llc. Influenza hemagglutinin and neuraminidase variants
EP2344893B1 (en) 2008-09-16 2014-10-15 Ibis Biosciences, Inc. Microplate handling systems and methods
WO2010033599A2 (en) 2008-09-16 2010-03-25 Ibis Biosciences, Inc. Mixing cartridges, mixing stations, and related kits, systems, and methods
US8148163B2 (en) 2008-09-16 2012-04-03 Ibis Biosciences, Inc. Sample processing units, systems, and related methods
US9233148B2 (en) * 2009-01-09 2016-01-12 Samuel Bogoch Replikin-based compounds for prevention and treatment of influenza and methods of differentiating infectivity and lethality in influenza
EP2396803A4 (en) 2009-02-12 2016-10-26 Ibis Biosciences Inc IONIZATION PROBE ASSEMBLIES
CN102361649A (zh) 2009-02-12 2012-02-22 米迪缪尼有限公司 流感血凝素和神经氨酸酶变体
AU2010270722B2 (en) 2009-07-06 2015-06-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
US9907746B2 (en) 2009-07-06 2018-03-06 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
US20110070254A1 (en) * 2009-07-10 2011-03-24 University Of Ottawa Mutations in the influenza a virus ns1 gene and use thereof
US9194877B2 (en) 2009-07-17 2015-11-24 Ibis Biosciences, Inc. Systems for bioagent indentification
US8950604B2 (en) 2009-07-17 2015-02-10 Ibis Biosciences, Inc. Lift and mount apparatus
ES2628739T3 (es) 2009-10-15 2017-08-03 Ibis Biosciences, Inc. Amplificación por desplazamiento múltiple
RU2420314C1 (ru) * 2009-12-02 2011-06-10 Федеральное государственное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФГУН ГНЦ ВБ "Вектор" Роспотребнадзора) Способ получения живой культуральной вакцины против вируса гриппа
CA2801151A1 (en) * 2010-06-01 2011-12-08 Novartis Ag Concentration of vaccine antigens with lyophilization
MX342138B (es) 2010-07-06 2016-09-14 Variation Biotechnologies Inc Composiciones y metodos para el tratamiento de influenza.
MX349294B (es) 2010-12-02 2017-07-21 Oncolytics Biotech Inc Formulaciones virales liofilizadas.
AU2011336413B2 (en) 2010-12-02 2015-01-22 Oncolytics Biotech Inc. Liquid viral formulations
CA2862871C (en) 2011-01-13 2020-09-22 Variation Biotechnologies Inc. Methods for preparing vesicles and formulations produced therefrom
CA2862864C (en) 2011-01-13 2018-12-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
US20140328876A1 (en) 2011-11-18 2014-11-06 Variation Biotechnologies Inc. Synthetic derivatives of mpl and uses thereof
US20140356399A1 (en) 2012-01-12 2014-12-04 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
US20150079077A1 (en) 2012-01-27 2015-03-19 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
CN102660511B (zh) * 2012-05-17 2013-08-21 肇庆大华农生物药品有限公司 一种降低血清中胰酶抑制物的方法及其应用
HK1218511A1 (zh) * 2013-03-13 2017-02-24 Novartis Ag 乙型流感病毒重配
CN104056276B (zh) * 2013-03-20 2017-05-10 上海生物制品研究所有限责任公司 一种流感病毒减毒活疫苗及其制备方法
WO2015063085A1 (en) 2013-10-28 2015-05-07 Thomas Muster Novel influenza virus vector for virotherapy
MA41506A (fr) * 2015-02-13 2017-12-19 Takeda Vaccines Inc Procédés de production de virus pour produire des vaccins
JP6722686B2 (ja) 2015-02-26 2020-07-15 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ｖｅｔｍｅｄｉｃａ ＧｍｂＨ 二価ブタインフルエンザウイルスワクチン
EP3601543A4 (en) * 2017-03-30 2021-01-27 Merck Sharp & Dohme Corp. ADDING NUCLEASES DIRECTLY TO CELL CULTURE TO FACILITATE DIGESTION AND RELEASE OF HOST CELL NUCLEIC ACIDS
WO2019090565A1 (zh) * 2017-11-09 2019-05-16 甘肃健顺生物科技有限公司 Vero驯化悬浮方法和二阶病毒生产工艺
WO2019133727A1 (en) 2017-12-29 2019-07-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Universal influenza virus probe set for enrichment of any influenza virus nucleic acid
CN112143693B (zh) * 2019-06-28 2024-12-27 杭州康万达医药科技有限公司 一种生产病毒的方法及收获液组合物
EP4110381A1 (en) 2020-02-27 2023-01-04 Takeda Vaccines, Inc. Method for removing host cell dna from virus preparation
CN117330750A (zh) * 2023-12-01 2024-01-02 北京生物制品研究所有限责任公司 一种筛选新冠病毒早期毒种的方法和制造疫苗的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753489A (en) * 1994-11-10 1998-05-19 Immuno Ag Method for producing viruses and vaccines in serum-free culture
KR100637937B1 (ko) * 1998-06-12 2006-10-23 마운트 시나이 스쿨 오브 메디신 오브 뉴욕 유니버시티 변형된 인터페론 길항물질을 보유하고, 백신 및 약제로사용되는 약독화된 네거티브 가닥 바이러스
AT408615B (de) * 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
O.KISTNER ET AL.DEVELOPMENT OF A MAMMALIAN CELL (VERO).......VACCINE16 9/10.1998,16(9/10),960-968.
O.KISTNER ET AL.DEVELOPMENT OF A MAMMALIAN CELL (VERO).......VACCINE16 9/10.1998,16(9/10),960-968. *
O.KISTNER ET AL.DEVELOPMENT OF A VERO CELL DERIVED........DEV. BIOL. STAND.98.1999,98101-110. *

Also Published As

Publication number Publication date
WO2002024876A3 (en) 2003-08-28
CA2423038A1 (en) 2002-03-28
JP2004509903A (ja) 2004-04-02
WO2002024876A2 (en) 2002-03-28
EP1358319A2 (en) 2003-11-05
CN1582333A (zh) 2005-02-16
DE60139026D1 (de) 2009-07-30
KR100927517B1 (ko) 2009-11-17
KR20080043891A (ko) 2008-05-19
JP5063852B2 (ja) 2012-10-31
EP1358319B1 (en) 2009-06-17
US7494659B2 (en) 2009-02-24
ES2327103T3 (es) 2009-10-26
ATE434035T1 (de) 2009-07-15
US20040137013A1 (en) 2004-07-15
AU2356002A (en) 2002-04-02
AU2002223560B2 (en) 2006-06-29
CA2423038C (en) 2012-03-13
DK1358319T3 (da) 2009-10-05
KR20030061810A (ko) 2003-07-22

Similar Documents

Publication Publication Date Title
CN1582333B (zh) 活疫苗及生产方法
EP1213030B1 (en) Method for producing biologicals in protein-free culture
US6146873A (en) Production of orthomyxoviruses in monkey kidney cells using protein-free media
JP4771959B2 (ja) インフルエンザウイルス作製のための多重プラスミド系
JP5686741B2 (ja) インフルエンザワクチンの生成
JP5349049B2 (ja) インフルエンザウイルス製造用マルチプラスミド系
AU2002223560A1 (en) Live influenza vaccine and method of manufacture
CN103540568A (zh) 制备流感病毒的多质粒系统
JP2009511073A6 (ja) インフルエンザウイルス製造用マルチプラスミド系
CN113853215A (zh) 高生长流感病毒
EP1748790B1 (en) Multi plasmid system for the production of influenza virus
Holtz et al. Production of a recombinant influenza vaccine using the baculovirus expression vector system
HK40060079A (en) High growth influenza virus
HK1154892A (en) Method for producing influenza virus in protein-free cell culture medium
HK1002285B (en) Method for producing biologicals in protein-free culture
HK1019233B (en) Animal cells and processes for the replication of influenza viruses

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100616

Termination date: 20160925

CF01 Termination of patent right due to non-payment of annual fee